Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nonmyeloablative allogeneic hematopoietic stem cell transplantation (Beth Israel Deaconess Medical Center)
- Development stage
- Phase 3
- Lead developer
- Beth Israel Deaconess Medical Center
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
A clinical procedure involving nonmyeloablative (reduced-intensity) allogeneic hematopoietic stem cell transplantation (NST) developed and investigated at Beth Israel Deaconess Medical Center. The approach aims to treat metastatic solid tumors by using a conditioning regimen of cyclophosphamide and fludarabine to suppress the host immune system, followed by the infusion of donor-derived peripheral blood stem cells. The therapeutic effect is primarily mediated by the 'graft-versus-tumor' (GVT) effect, where donor-derived T-cells recognize and eliminate residual cancer cells. This modality is particularly explored for patients with renal cell carcinoma, breast cancer, and other solid tumors who have failed standard therapies, utilizing donor lymphocyte infusions (DLI) to further stimulate anti-tumor immunity if needed.
- Other names
- Nonmyeloablative allogeneic stem cell transplantationNSTReduced-intensity conditioning allogeneic stem cell transplantationNon-myeloablative allogeneic hematopoietic stem cell transplantation
Beyond the preview
Go deeper on Nonmyeloablative allogeneic hematopoietic stem cell transplantation (Beth Israel Deaconess Medical Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nonmyeloablative allogeneic hematopoietic stem cell transplantation (Beth Israel Deaconess Medical Center).